jes extender sizegenetics review - sizegenetics extender best
http://soundandsecure.net/sizegenetics There are many penis extender review sites out there, and they are all saying the same thing... that SizeGenetics trade; is ...

By: SizegeneticsSuper

Go here to read the rest:
jes extender sizegenetics review - sizegenetics extender best - Video

Recommendation and review posted by Bethany Smith

male enhancement exercises sizegenetics review - sizegenetics extender best
http://soundandsecure.net/sizegenetics There are many penis extender review sites out there, and they are all saying the same thing... that SizeGenetics trade; is ...

By: SizegeneticsSuper

Here is the original post:
male enhancement exercises sizegenetics review - sizegenetics extender best - Video

Recommendation and review posted by Bethany Smith

Impeccably Distinguished YGS #50 Submission
Links for comment image files below. Sorry Jack, hope you don #39;t mind. I am too incompetent to put them in myself. First comment: http://i724.photobucket.com/...

By: phoenixmage

Originally posted here:
Impeccably Distinguished YGS #50 Submission - Video

Recommendation and review posted by Bethany Smith

dna
please subscribe and like all my videos this girl has a huge dream.

By: holly dixon

Read more from the original source:
dna - Video

Recommendation and review posted by Bethany Smith

2013 Breeders Select Prospect Goat Sale
2013 Masterpiece Genetics.

By: BreedersSelect

See the rest here:
2013 Breeders Select Prospect Goat Sale - Video

Recommendation and review posted by Bethany Smith

Season 2, Meeting 5: The Genetics of Speciation

By: Rafael Maia

Continue reading here:
Season 2, Meeting 5: The Genetics of Speciation - Video

Recommendation and review posted by Bethany Smith

Ep 297 Purple Lemon Sour Diesel (*^ ^)* Hd Strain Flower Review Medical Marijuana weed bud
Ep 297 is here in full 720p Hd ^^ - thumbs up , comment and sub ^^ - audio is Wiz Khalifa and Curren$y - Car Service and The Planes - Strain Flower Review ...

By: SOMAWEEDLOVE

Originally posted here:
Ep 297 Purple Lemon Sour Diesel (*^ ^)* Hd Strain Flower Review Medical Marijuana weed bud - Video

Recommendation and review posted by Bethany Smith

A Variety of Patterns
Produced for BIO137 (Plant Genetics), Spring 2013.

By: Plant Genetics

Read the original:
A Variety of Patterns - Video

Recommendation and review posted by Bethany Smith

FRESH MEAT! (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Want some gear? US Store: http://seananners.spreadshirt.com EU Store: http://seananners.spreadshirt....

By: SeaNanners

More here:
FRESH MEAT! (The Hidden) - Video

Recommendation and review posted by Bethany Smith

Will Bodybuilding Make Me Weaker?
Sign up Grow Stronger Newsletter: http://hulsestrength.com/go/youtube Elliott #39;s Other Channel: http://www.youtube.com/user/elliottsaidwhat Elliott #39;s Facebook...

By: strengthcamp

See original here:
Will Bodybuilding Make Me Weaker? - Video

Recommendation and review posted by Bethany Smith

SAN JOSE, CA, April 6, 2013 /PRNewswire/ - The American College of Medical Genetics (ACMG) issued a position statement to support the use of non-invasive prenatal screening (NIPS) in women with singleton pregnancies. The statement can be found at this link: http://www.acmg.net/docs/nips-GiM_galley_text_130301.pdf

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

The statement clearly emphasizes NIPS as a screening, and not diagnostic, test. It goes on to highlight the advantages of higher detection rates and lower false positives rates associated with NIPS versus maternal serum screening, and it underscored the importance of first trimester ultrasound regardless of screening modality. ACMG recommends both pre-test and post-test counseling to inform women about NIPS tests in regards to benefits and limitations. As a screening test, NIPS can lead to both false positive and false negative results.

NIPS with the Harmony Prenatal Test has been studied in more than 6,000 women to date across multiple studies. Ariosa shares ACMG's view that NIPS is a safe and effective prenatal testing option for pregnant women and that it should be responsibly introduced into clinical practice.

"ACMG's statement provides ongoing support of non-invasive prenatal screening with cell-free DNA as a major clinical advance," said Ken Song, CEO of Ariosa Diagnostics. "Our commitment to responsible introduction of this screening technology will help women manage the health of their pregnancy and fetus.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visitwww.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT: Jen Bruursema Ariosa Diagnostics 202-316-4553 jbruursema@ariosadx.com

More:
American College of Medical Genetics Supports Non-invasive Prenatal Screening for Fetal Aneuploidy Detection in ...

Recommendation and review posted by Bethany Smith

RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 90,000 shares of its common stock, at a price to the public of $10.00 per share, in connection with its previously announced underwritten initial public offering of 600,000 shares of common stock, bringing expected total gross proceeds from the offering to $6,900,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.

Aegis Capital Corp. is acting as sole book-running manager for the offering.

Feltl and Company, Inc. is acting as co-manager for the offering.

This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 4, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cancer Genetics:

Cancer Genetics, Inc. is an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis and response to treatment (theranosis) of cancer. The proprietary tests being developed by Cancer Genetics target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers. Cancer Genetics recently has begun to provide its proprietary tests and services along with a comprehensive range of non-proprietary oncology-focused tests and laboratory services that it has provided historically to oncologists and pathologists at hospitals, cancer centers and physician offices. Cancer Genetics is currently offering its tests and laboratory services in its 17,936 square foot laboratory located in Rutherford, New Jersey, which has been accredited under the Clinical Laboratory Improvement Amendments of 1988 to perform high complexity testing.

Read the rest here:
Cancer Genetics , Inc. Announces Full Exercise of Over-Allotment Option

Recommendation and review posted by Bethany Smith

Bodyshock - The Boy In The Bubble - David Vetter - Part 1
David Vetter (September 21, 1971 -- February 22, 1984) became famous for living in a sterile environment. He was born with severe combined immunodeficiency (...

By: SamuraiMivec

Visit link:
Bodyshock - The Boy In The Bubble - David Vetter - Part 1 - Video

Recommendation and review posted by Bethany Smith

Bodyshock - The Boy In The Bubble - David Vetter - Part 2
David Vetter (September 21, 1971 -- February 22, 1984) became famous for living in a sterile environment. He was born with severe combined immunodeficiency (...

By: SamuraiMivec

More here:
Bodyshock - The Boy In The Bubble - David Vetter - Part 2 - Video

Recommendation and review posted by Bethany Smith

Bodyshock - The Boy In The Bubble - David Vetter - Part 3
David Vetter (September 21, 1971 -- February 22, 1984) became famous for living in a sterile environment. He was born with severe combined immunodeficiency (...

By: SamuraiMivec

More:
Bodyshock - The Boy In The Bubble - David Vetter - Part 3 - Video

Recommendation and review posted by Bethany Smith

Bodyshock - The Boy In The Bubble - David Vetter - Part 4
David Vetter (September 21, 1971 -- February 22, 1984) became famous for living in a sterile environment. He was born with severe combined immunodeficiency (...

By: SamuraiMivec

Link:
Bodyshock - The Boy In The Bubble - David Vetter - Part 4 - Video

Recommendation and review posted by Bethany Smith

WEST CHESTER, Pa., April 4, 2013 /PRNewswire/ --QVC and the Fashion Footwear Association of New York (FFANY), building on a 19 year philanthropic relationship supporting breast cancer research, have announced a $140,000 grant to fund research at The Wistar Institute on a specific and deadly form of breast cancer called triple negative.

"The mission of the QVC-FFANY relationship is to support the most promising research with the potential to end breast cancer," said Mike George, president and CEO of QVC. "We are proud to support The Wistar Institute's work as it holds great promise for developing new treatments for breast cancer and saving women's lives." QVC addresses critical health issues for women by working with organizations, like FFANY, to invest in life-saving research.

Close to 300, 000 women are diagnosed with breast cancer each year. Of these, nearly one in four breast cancer cases is classified as triple negative. Triple negative patients have a higher rate of relapse following treatment than other breast cancer patients, and therefore, have lower overall survival rates.

Triple negative patients have tumors that are missing three proteins found in normal cells. These proteins are critical to deciphering chemical signals, like those from hormones. The laboratory of Dario Altieri, M.D., Director of The Wistar Institute Cancer Center, set out to discover how triple negative breast cancers survive without these important proteins and, in doing so, they found a common factor. Since cells require these signals in order to grow and divide, triple negative breast cancer cells survive by using a gene that is normally "switched off" in adults: Notch-1. While the road to creating therapies is a long one, Altieri is committed to advancing research of Notch- 1 with the ultimate goal of developing new treatments for triple negative breast cancer.

"This funding will help us develop better, more targeted therapies against this highly aggressive form of breast cancer," Altieri said. "We are grateful to QVC and FFANY for their vision in ensuring this promising line of research moves forward."

This year, QVC and FFANY will celebrate 20 years of the QVC Presents "FFANY Shoes On Sale" broadcast, which has donated more than $40 million for breast cancer research and education.

About The Wistar Institute The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today's Discoveries Tomorrow's Cures. On the Web at http://www.wistar.org.

About the Fashion Footwear Charitable Foundation The Fashion Footwear Charitable Foundation was created to support ongoing research and education programs in the fight against breast cancer and is supported by members of the Fashion Footwear Association of New York (FFANY). Donated footwear is sold on live television through QVC during the Fashion Footwear Charitable Foundation's annual charity benefit, QVC Presents "FFANY Shoes on Sale." Net proceeds are distributed to leading breast cancer research and education institutions across the United States, including beneficiaries for the 2012 event: The Abramson Cancer Center of the University of Pennsylvania, The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, The Breast Cancer Research Foundation, The John Wayne Cancer Institute Breast Center at Saint John's Health Center, The Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, The Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, The University of Michigan Comprehensive Cancer Center's Breast Oncology Program, The University of Pittsburgh Cancer Institute and The Winthrop P. Rockefeller Cancer Institute of the University of Arkansas for Medical Sciences. The Fashion Footwear Charitable Foundation makes its home at 274 Madison Avenue, Suite 1701, New York, NY 10016, http://www.FFANY.org.

About QVC QVC, Inc., a wholly owned subsidiary of Liberty Interactive Corporation (LINTA), is the world's leading video and ecommerce retailer. QVC is committed to providing its customers with thousands of the most innovative and contemporary beauty, fashion, jewelry and home products. Its programming is distributed to approximately 250 million homes worldwide through operations in the U.S., Japan, Germany, United Kingdom, Italy and a joint venture in China. West Chester, Pa.-based QVC has shipped more than a billion packages in its 26-year history and the company's website, QVC.com, is ranked among the top general merchant Internet sites. QVC, Q, and the Q Ribbon Logo are registered service marks of ER Marks, Inc.

Follow this link:
QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5cl4b2/drug_delivery_in) has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.

Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.

Innovative cancer therapies are based on current concepts of molecular biology of cancer. These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.

Several innovative methods of drug delivery are used in cancer. These include use of microparticles as carriers of anticancer agents. These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors.

Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described.

Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors.

The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2012-2022 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.

Profiles of 227 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 256 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 10 figures.

Key Topics Covered:

See the original post here:
Research and Markets: Drug Delivery in Cancer - Technologies, Markets and Companies - Updated 2013 Report with More ...

Recommendation and review posted by Bethany Smith

WARSAW, Poland, April 4,2013 /PRNewswire/ --IBM (NYSE: IBM)Blue Gene/Q, the most powerful single architecture supercomputer in Poland, has been chosen by The Interdisciplinary Centre for Mathematical and Computational Modeling, University of Warsaw (ICM) of Poland to support the country's largest biomedical and biotechnological research initiative called, "Centre for Pre-clinical Research and Technology (CePT)." More than 500 life sciences and biomedical researchers, physicians and students, from a consortium led by The Medical University of Warsaw (WUM) and consisting of three universities and seven research centers of the Polish Academy of Sciences, will use the supercomputer and its supporting e-infrastructure to gain further insight into chronic diseases.

(Photo: http://photos.prnewswire.com/prnh/20130404/NY89105-INFO )

(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO )

"CePT, a EUR 100 million project, aims to support Poland's transition towards more preventive and patient-centric healthcare," said Dr. Robert Sot, Director of CePT, Warsaw University. "The project will allow the medical community to provide a more holistic approach and open collaboration for the development of innovative treatments and drugs that will improve patients' quality of life over the long term."

Estimations show that over one-fourth of Poland's aging population has developed at least one or, very often, more chronic diseases such as: cancer, diabetes, heart disease, respiratory conditions, stroke, and neurological disorders. Early detection and timely diagnosis of these diseases translate into well-targeted and optimized healthcare, as well as improved quality of a patient's life. Similar demands could stimulate the need to carry out clinical and pre-clinical tests covering three to five million Polish citizens, and generate massive volumes of valuable health data which can, in turn, be used by laboratories.

ICM's new Blue Gene/Q, code named Nostromo, will help scientists process up to 16 terabytes of Big Data per one sequence by running compute-intensive simulations at the speed of 209.7 trillion operations per second. The supercomputer will use algorithms moving beyond the "routine" sequencing of human or animal genomes, to tackle more complex processes that will reveal the rare variants in human genetics, (i.e. those that cause predispositions to Alzheimer's, cancer, diabetes, downs syndrome, etc.). By understanding what prevents protein molecules, which build and maintain human bodies, from folding up properly and triggering a disease, scientists will be able to develop a new drug or treatment, (i.e. "build" their own molecules or block the action of undesirable enzymes).

"The process of developing and generating a new drug or treatment normally takes up to three years, and costs have nearly quadrupled in the past 15 years," said Prof. Marek Niezgodka, Director of ICM. "With Nostromo, we expect to increase the simulation speed which will bring us much closer to the era of "personalized medicine," when preventative approaches can be tailored to a specific condition."

Nostromo currently ranks N 143 on the Top500.org list and N 9 on Green500.org. The system has already been installed by IBM Poland and Qumak SA, IBM's Business Partner.

"IBM delivered the most powerful single architecture supercomputer for the ICM of Poland. Nostromo is able to process up to 16 TB of Big Data per one sequence by running simulations at the speed of 210 TFLOPS," said Ales Bartunek, Country General Manager, IBM Poland and Baltics. "We are confident that the POWER based Blue Gene/Q has the potential to save years of research and help scientists take healthcare in Poland to the next level."

About Nostromo

Here is the original post:
ICM's New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland

Recommendation and review posted by Bethany Smith

Police State USA: Monsanto Protection Act Will KILL Our Future Children! Get Involved!
FB Page: http://www.facebook.com/NomadicMedHunter My Google+ https://plus.google.com/u/0/ I know this was a bit lengthy, but I wanted to get it all out. I fe...

By: Nomadic Medhunter

Read more:
Police State USA: Monsanto Protection Act Will KILL Our Future Children! Get Involved! - Video

Recommendation and review posted by Bethany Smith

DUBLIN, April 4, 2013 /PRNewswire/ --

Research and Markets announces the addition of AOCS Press' book "Palm Oil: Production, Processing, Characterization, and Use" to its catalogue.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This book serves as a rich source of information on the production, processing, characterization and utilization of palm oil and its components. It also includes several topics related to oil palm genomics, tissue culture and genetic engineering of oil palm.

Physical, chemical and polymorphic properties of palm oil and its components as well as the measurement and maintenance of palm oil quality are included and may be of interest to researchers and food manufacturers.

General uses of palm oil/kernel oil and their fractions in food, nutritional and oleochemical products are discussed as well as the potential use of palm oil as an alternative to trans fats.

Some attention is also given to palm biomass, bioenergy, biofuels, waste management, and sustainability.

Topics Covered:

A Brief History of the Oil Palm

Breeding and Genetics of the Oil Palm

See more here:
Palm Oil: Production, Processing, Characterization, and Use

Recommendation and review posted by Bethany Smith

Public release date: 4-Apr-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, April 4, 2013Pet therapy can help patients cope with the pain, stress, and emotional effects of a serious illness, but access to a companion animal is not always possible. Robotic animals may offer the same benefits, as explored in a fascinating study presented in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free online on the Cyberpsychology, Behavior, and Social Networking website.

Sandra Okita, PhD, Columbia University (New York, NY) evaluated the effectiveness of robotic companions to reduce feelings of pain and emotional anxiety among pediatric patients and their parents. In the article "Self-Other's Perspective Taking: The Use of Therapeutic Robot Companions as Social Agents for Reducing Pain and Anxiety in Pediatric Patients," Dr. Okita reports that when a child and parent were together during robot therapy sessions, the patients' pain ratings decreased significantly. There were no differences in the pain ratings when the child interacted with the robot animal without the parent present.

Additionally, when the parent and child were together for the robot therapy sessions, as the parent's pain rating decreased, so did the patient's, which the author attributes to "parental modeling." Children learn how to cope with emotions such as fear and anxiety by observing how an adult responds and behaving in a similar manner.

"It will be useful to explore in future studies whether the benefit of parental modeling exhibited during the interactions is maintained long-term," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA. "It will also be important to understand how we may lower pain and anxiety in children without the presence of their parents, which is of course not always feasible in a hospital setting."

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

Follow this link:
Can therapy using robots reduce pain and anxiety among pediatric patients?

Recommendation and review posted by Bethany Smith

BIRMINGHAM, Alabama -- Hungry mice might eventually lead the way to protect against Alzheimer's disease, a promising UAB study suggests.

Previous studies have shown that cutting calories may protect against Alzheimer's and other degenerative brain disorders. But this study, published this week in the journal PLOS ONE, is believed to be the first to find that the feeling of hunger alone may be the protection.

To understand this, one must look at the research which involved mouse swimming, maze running, chocolate pills and genetic engineering.

Researchers used three groups of 12 mice, which had been genetically engineered to have the mutations known to cause Alzheimer's disease, said Inga Kadish, senior author of the study.

"One group got to eat to their heart's desire," said Kadish, assistant professor in the Department of Cell, Developmental and Integrative Biology in UAB's School of Medicine.

Or as Kadish put it: "The Western diet."

The second group of mice got a 20 percent caloric cut in their diet.

The third group, and this is the important one, was given a synthetic hormone which made them feel mildly hungry all the time, no matter how much they ate.

The synthetic hormone called ghrelin agonist, was given to the third group in a chocolate pill. The other groups, even the low-cal group, got a chocolate pill as a placebo without the ghrelin.

The mice were put through a series of tests to determine their cognitive skills, including an elevated maze and a water maze. In the water maze, for example, the mice swam around trying to find a hidden platform within 60 seconds. If the mouse doesn't find it, it is put on the platform. Normal mice will remember the platform and find it quicker with each dive in the pool.

Go here to see the original:
Hungry mice may lead the way to Alzheimer's treatment

Recommendation and review posted by Bethany Smith

Public release date: 4-Apr-2013 [ | E-mail | Share ]

Contact: Alex Lyda alex.lyda@utsouthwestern.edu 214-648-3404 UT Southwestern Medical Center

DALLAS April 4, 2013 Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells a specific genetic weakness that can be exploited for new therapies.

Although researchers have long known that mutant versions of the KRAS gene drive tumor formation and are key to cell survival in non-small cell lung cancer, the blocking of activated KRAS has proven difficult. For years, investigations have explored stopping lung cancer at this junction, which also would have an impact on many other cancers. KRAS mutations, for instance, account for as much as 50 percent of all colon cancers.

"There is an urgent need to identify 'downstream' pathways that are required to sustain and grow non-small cell lung cancer (NSCLC)," said Dr. Pier Paolo Scaglioni, assistant professor of internal medicine and a member of the Harold C. Simmons Cancer Center. "As we focus on the right pathways, we stand a much better chance of chemically blocking them and stopping tumor growth."

The team's findings are published in the April edition of Cancer Discovery, a journal of the American Association for Cancer Research. Dr. Scaglioni served as senior author and Dr. Georgia Konstantinidou, a postdoctoral researcher, was first author.

To identify vulnerabilities in KRAS-mutant tumors, Dr. Scaglioni's group used a mouse model of high-grade lung adenocarcinoma induced by a recombinant transgene that allows activation of mutant KRAS in the respiratory epithelium. This strategy allows the generation of high-grade lung cancers that closely resemble human tumors.

Compared with control tumors, the investigators found that the protein RHOA was specifically required for the survival and growth of high-grade tumors via activation of a focal adhesion kinase (FAK). Consistent with a critical role for this pathway in NSCLC, activation of RHOA and FAK was observed in human NSCLC samples and human lung-cancer cells were found to be highly sensitive to pharmacologic inhibitors of FAK.

FAK is a protein that helps cells stick to each other and their surroundings, and also aids in determining how rigid and mobile the cell's structure is. When FAK is blocked in breast cancer, the cancer cells become less metastastic due to decreased mobility.

Dr. Scaglioni and his team are now poised to study in clinical trials the pharmacologic blockade of FAK using inhibitor compounds currently under commercial development.

See the original post here:
Genetic vulnerability of lung cancer to lay foundation for new drug options

Recommendation and review posted by Bethany Smith

Genetic markers that could help highlight who is at risk of developing Alzheimer's disease have been identified by US scientists.

The research in Neuron identifies mutations that affect the build-up of certain proteins in the brain.

High levels of these tau proteins increase the chance of having the disease.

UK experts said the study could help understand the changes that occur in the brains of Alzheimer's patients.

Tangles of a kind of tau called phosphorylated tau (ptau) are a hallmark of the disease.

One of the new gene variants identified by the Washington University School of Medicine team was also shown to be linked to a small increased risk of developing Alzheimer's and a greater risk of cognitive decline.

The team used genetic information from more than 1,200 people, significantly larger than previous studies in this area.

Dr Alison Goate, who led the study, said: "We anticipate that knowledge about the role of these genes in Alzheimer's disease may lead to the identification of new targets from therapies or new animal or cellular models of the disease.

Lifestyle 'plays a role' UK experts said the study adds to the number of genetic markers that have been linked to the development of Alzheimer's disease.

Dr Doug Brown, director of research and development at the Alzheimer's Society, said: "In discovering new genes that have a link to Alzheimer's, this robust study helps scientists to better understand the way the brain changes when dementia develops.

See the original post:
Early Genetic Markers Of Alzheimer's Risk Identified

Recommendation and review posted by Bethany Smith